<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1847">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446429</url>
  </required_header>
  <id_info>
    <org_study_id>AB-DRUG-SARS-004</org_study_id>
    <nct_id>NCT04446429</nct_id>
  </id_info>
  <brief_title>Anti-Androgen Treatment for COVID-19</brief_title>
  <official_title>Anti-Androgen Treatment for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Biology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Biology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to explore the possible protective role of anti-androgens in&#xD;
      SARS-CoV-2 infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the continuing SARS-CoV-2 (COVID-19) pandemic, several studies have reported a&#xD;
      significant difference in the rate of severe cases between adult females and adult males (42%&#xD;
      vs 58%).Among children under the age of 14, the rate of severe cases was reported to be&#xD;
      extremely low. To explain this difference, several theories have been proposed including&#xD;
      cigarette smoking and lifestyle habits. However, no theory fits both the gender difference in&#xD;
      severe cases as well as reduced risk in pre-pubescent children. Our past research on male&#xD;
      androgenetic alopecia (AGA) has led us to investigate an association between androgens and&#xD;
      COVID-19 pathogenesis. In normal subjects, androgen expression demonstrates significant&#xD;
      variation between men and women as well as between adults and pre-pubescent children.&#xD;
&#xD;
      SARS-CoV-2 primarily infects type II pneumocytes in the human lung. SARS-CoV-2 enters&#xD;
      pneumocytes, by anchoring to the ACE2 cell surface receptor. Prior to receptor binding, viral&#xD;
      spike proteins undergo proteolytic priming by the transmembrane protease, serine 2 (TMPRSS2).&#xD;
      TMPRSS2 inhibition or knock down reduces ability of SARS-CoV-1 (a related virus to&#xD;
      SARS-CoV-2) to infect cells in vitro. Additionally, TMPRSS2 also facilitates entry of&#xD;
      influenza A and influenza B into primary human airway cells and type II pneumocytes.&#xD;
&#xD;
      The human TMPRSS2 gene has a 15 bp androgen response element and in humans, androgens are the&#xD;
      only known transcription promoters for the TMPRSS2 gene. In a study of androgen-stimulated&#xD;
      prostate cancer cells (LNCaP), TMPRSS2 mRNA expression increase was mediated by the androgen&#xD;
      receptor. Further, the ACE2 receptor, also critical for SARS-CoV-2 viral infectivity, is&#xD;
      affected by male sex hormones with higher activity found in males.&#xD;
&#xD;
      Androgenetic alopecia (AGA), often referred to as male pattern hair loss, is the most common&#xD;
      form of hair loss among men. The development of androgenetic alopecia is androgen mediated&#xD;
      and is dependent on genetic variants found in the androgen receptor gene located on the X&#xD;
      chromosome; thus, it is hypothesized that men with AGA would be more prone to severe COVID-19&#xD;
      disease. The investigators conducted a preliminary observational study of hospitalized&#xD;
      COVID-19 patients at two Spanish tertiary hospitals between March 23-April 6, 2020 to test&#xD;
      this theory. In total, 41 Caucasian males admitted to the hospitals with a diagnosis of&#xD;
      bilateral SARS-CoV-2 pneumonia were analyzed. The mean age of patients was 58 years (range&#xD;
      23-79). Among them, 29 (71%) were diagnosed with AGA (16 (39%) were classified as severe AGA&#xD;
      (Hamilton IV or above)) and 12 (29%) did not present clinical signs of AGA. The diagnosis of&#xD;
      AGA was performed clinically by a dermatologist. The precise prevalence of AGA among&#xD;
      otherwise healthy Spanish Caucasian males is unknown; however, based on published literature,&#xD;
      the expected prevalence of a similar age-matched Caucasian population is approximately&#xD;
      31-53%.&#xD;
&#xD;
      Based on the scientific rationale combined with this preliminary observation, the&#xD;
      investigators propose to test an anti-androgen as a treatment for patients recently diagnosed&#xD;
      with COVID-19.&#xD;
&#xD;
      We have chosen the use of the novel second generation androgen receptor (AR) antagonist&#xD;
      proxalutamide as a means for rapid reduction in AR activity. Proxalutamide (GT0918)&#xD;
      demonstrates a dual mechanism of action. It is highly effective in inhibiting AR as well as&#xD;
      exhibiting pharmacological effects of inducing the down-regulation of AR expression; the&#xD;
      mechanism that is not present in bicalutamide and enzalutamide. Additionally, it has been&#xD;
      reported that Proxalutamide lowers the expression of ACE2. Both would be beneficial for&#xD;
      preventing SARS-CoV-2 entry into lung cells.&#xD;
&#xD;
      This study is intended to explore the possible protective role of anti-androgens in&#xD;
      SARS-CoV-2 infection. Provided anti-androgens are effective in reducing the rate of COVID-19&#xD;
      hospitalization, subjects enrolled in this study may experience a lower rate of&#xD;
      hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Actual">January 21, 2021</completion_date>
  <primary_completion_date type="Actual">December 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 Hospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of subjects hospitalized due to COVID-19</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV2</condition>
  <condition>Androgenetic Alopecia</condition>
  <condition>Prostate Cancer</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care as determined by the PI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proxalutamide + Standard Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proxalutamide + standard of care as determined by the PI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proxalutamide</intervention_name>
    <description>200 mg q.d.</description>
    <arm_group_label>Proxalutamide + Standard Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care as determined by the PI</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male age ≥18 years old&#xD;
&#xD;
          2. Laboratory confirmed positive SARS-CoV-2 rtPCR test within 7 days prior to&#xD;
             randomization&#xD;
&#xD;
          3. Clinical status on the COVID-19 8-point Ordinal Scale of 1 or 2&#xD;
&#xD;
          4. Coagulation: INR ≤ 1.5×ULN, and APTT ≤ 1.5×ULN&#xD;
&#xD;
          5. Subject (or legally authorized representative) gives written informed consent prior to&#xD;
             any study screening procedures&#xD;
&#xD;
          6. Subject (or legally authorized representative) agree that subject will not participate&#xD;
             in another COVID-19 trial while participating in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject enrolled in a study to investigate a treatment for COVID-19&#xD;
&#xD;
          2. Subject taking an anti-androgen of any type including: androgen depravation therapy,&#xD;
             5-alpha reductase inhibitors, etc…&#xD;
&#xD;
          3. Patients who are allergic to the investigational product or similar drugs (or any&#xD;
             excipients);&#xD;
&#xD;
          4. Subjects who have malignant tumors in the past 5 years, with the exception of&#xD;
             completed resected basal cell and squamous cell skin cancer and completely resected&#xD;
             carcinoma in situ of any type&#xD;
&#xD;
          5. Subjects with known serious cardiovascular diseases, congenital long QT syndrome,&#xD;
             torsade de pointes, myocardial infarction in the past 6 months, or arterial&#xD;
             thrombosis, or unstable angina pectoris, or congestive heart failure which is&#xD;
             classified as New York Heart Association (NYHA) class 3 or higher, or left ventricular&#xD;
             ejection fraction (LVEF) &lt; 50%, QTcF &gt; 450 ms&#xD;
&#xD;
          6. Subjects with uncontrolled medical conditions that could compromise participation in&#xD;
             the study(e.g. uncontrolled hypertension, hypothyroidism, diabetes mellitus)&#xD;
&#xD;
          7. Known diagnosis of human immunodeficiency virus(HIV) , hepatitis C, active hepatitis&#xD;
             B, treponema pallidum (testing is not mandatory）&#xD;
&#xD;
          8. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) &gt; 5 times the upper limit&#xD;
             of normal.&#xD;
&#xD;
          9. Estimated glomerular filtration rate (eGFR) &lt; 30 ml/min&#xD;
&#xD;
         10. Severe kidney disease requiring dialysis&#xD;
&#xD;
         11. Subject unlikely to return for day 15 site visit for reasons other then remission&#xD;
&#xD;
         12. Subject (or legally authorized representative) not willing or unable to provide&#xD;
             informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio A Cadegiani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corpometria Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andy Goren, MD</last_name>
    <role>Study Director</role>
    <affiliation>Applied Biology, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Corpometria Institute</name>
      <address>
        <city>Brasilia</city>
        <zip>70390-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Goren A, McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Dhurat R, Washenik K, Lotti T. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020 Jul;33(4):e13365. doi: 10.1111/dth.13365. Epub 2020 Apr 8.</citation>
    <PMID>32237190</PMID>
  </reference>
  <reference>
    <citation>Goren A, Vaño-Galván S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, Shapiro J, Sinclair RD, Gold MH, Kovacevic M, Mesinkovska NA, Goldust M, Washenik K. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul;19(7):1545-1547. doi: 10.1111/jocd.13443. Epub 2020 Apr 23.</citation>
    <PMID>32301221</PMID>
  </reference>
  <reference>
    <citation>McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Sinclair R, Ramos PM, Washenik K, Andrade M, Herrera S, Goren A. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul;19(7):1542-1543. doi: 10.1111/jocd.13455. Epub 2020 Jun 14.</citation>
    <PMID>32333494</PMID>
  </reference>
  <reference>
    <citation>Wambier CG, Goren A, Vaño-Galván S, Ramos PM, Ossimetha A, Nau G, Herrera S, McCoy J. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020 Nov;81(7):771-776. doi: 10.1002/ddr.21688. Epub 2020 May 15.</citation>
    <PMID>32412125</PMID>
  </reference>
  <reference>
    <citation>Wambier CG, Vaño-Galván S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard Á, Moreno-Arrones OM, Jiménez-Gómez N, González-Cantero A, Fonda-Pascual P, Segurado-Miravalles G, Shapiro J, Pérez-García B, Goren A. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The &quot;Gabrin sign&quot;. J Am Acad Dermatol. 2020 Aug;83(2):680-682. doi: 10.1016/j.jaad.2020.05.079. Epub 2020 May 22.</citation>
    <PMID>32446821</PMID>
  </reference>
  <reference>
    <citation>Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, Prayer-Galetti T, Alimonti A. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020 Aug;31(8):1040-1045. doi: 10.1016/j.annonc.2020.04.479. Epub 2020 May 6.</citation>
    <PMID>32387456</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <results_first_submitted>January 22, 2021</results_first_submitted>
  <results_first_submitted_qc>January 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 3, 2021</results_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-Androgen</keyword>
  <keyword>Proxalutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT04446429/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Care</title>
          <description>Standard of care as determined by the PI&#xD;
Standard of Care: Standard of care as determined by the PI</description>
        </group>
        <group group_id="P2">
          <title>Proxalutamide + Standard Care</title>
          <description>Proxalutamide + standard of care as determined by the PI&#xD;
Proxalutamide: 200 mg q.d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Care</title>
          <description>Standard of care as determined by the PI&#xD;
Standard of Care: Standard of care as determined by the PI</description>
        </group>
        <group group_id="B2">
          <title>Proxalutamide + Standard Care</title>
          <description>Proxalutamide + standard of care as determined by the PI&#xD;
Proxalutamide: 200 mg q.d.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="262"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="10.8"/>
                    <measurement group_id="B2" value="44.2" spread="14"/>
                    <measurement group_id="B3" value="44.5" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Mixed ethnicity (Brazil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coexisting conditions</title>
          <description>At least one coexisting conditions: Type 2 diabetes, Hypertension, COPD and Obesity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>COVID-19 Hospitalization</title>
        <description>Percentage of subjects hospitalized due to COVID-19</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Care</title>
            <description>Standard of care as determined by the PI&#xD;
Standard of Care: Standard of care as determined by the PI</description>
          </group>
          <group group_id="O2">
            <title>Proxalutamide + Standard Care</title>
            <description>Proxalutamide + standard of care as determined by the PI&#xD;
Proxalutamide: 200 mg q.d.</description>
          </group>
        </group_list>
        <measure>
          <title>COVID-19 Hospitalization</title>
          <description>Percentage of subjects hospitalized due to COVID-19</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Care</title>
          <description>Standard of care as determined by the PI&#xD;
Standard of Care: Standard of care as determined by the PI</description>
        </group>
        <group group_id="E2">
          <title>Proxalutamide + Standard Care</title>
          <description>Proxalutamide + standard of care as determined by the PI&#xD;
Proxalutamide: 200 mg q.d.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="128"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="128"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="128"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="57" subjects_affected="57" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="128"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="128"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="128"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="128"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="128"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="128"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Applied Biology</organization>
      <phone>+1-949-387-4526</phone>
      <email>monican@appliedbiology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

